Treatment sequencing in advanced mCRC patients

COR2ED Medical Education

Το περιεχόμενο παρέχεται από το COR2ED. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον COR2ED ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

2y ago 21:09

MP3•Αρχική οθόνη επεισοδίου

COR2ED Medical Education: This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond. Dr Shubham Pant from MD Anderson Cancer Center, Houston Texas USA and Dr Jenny Seligmann from the University of Leeds, UK discuss treatment considerations in these patients and evaluate recent data.

The experts discuss the treatments currently approved at third line – regorafenib and TAS-102 (trifluridine/tipiracil). They also reflect on data presented at ASCO GI 2023 from the SUNLIGHT trial which studied the use of TAS-102 plus bevacizumab as third-line treatment in refractory colorectal cancer and where this treatment may fit into the treatment sequence in the future. They also look at data from the FRESCO-2 trial which was presented at ESMO 2022 and studied fruquintinib in the later line mCRC setting.. The discussion then moves to treatments for molecularly selected mCRC patients with the MOUNTAINEER trial where a combination of trastuzumab and tucatinib was studied. Finally, they discuss EGFR rechallenge and data from the CRICKET and CHRONOS trials.

90 επεισόδια

#Science #COR2ED #Higher Education #Medical Education #Fitness #Podcasting Education #Medicine